Serum metabolic patterns reveal the diagnostic and prognostic role of alanine abnormality in ocular adnexal lymphoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published Date:

Abstract

Ocular adnexal lymphoma (OAL) is the most common orbital malignancy in adults. Advanced tools for precise diagnosis and prognosis of OAL are in demand. Here, the nanoparticle-enhanced laser desorption/ionization mass spectrometry was applied for the construction of OAL-associated serum metabolic patterns (SMPs) from 239 participants (104 OAL and 135 non-OAL). Through machine learning, the diagnostic performance with an area-under-the-curve (AUC) of 0.901 was achieved for OAL based on SMPs. Furthermore, a diagnostic metabolic panel was constructed with an AUC of 0.875. Moreover, a prognosis scoring system was built and its desirable prediction efficacy for progression-free survival of OAL was confirmed ( < 0.05). Specifically, the decreased serum alanine level was found to play both vital roles in the diagnosis and prognosis of OAL, and we demonstrated that uptake of alanine promotes glycolysis and cell growth in lymphoma cells. Our study highlights the value of the serum metabolite biomarkers in the clinical management of OAL.

Authors

  • Yida Huang
    School of Big Data and Software Engineering, Chongqing University, Chongqing, 401331, China.
  • Huimin Lin
    Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, NO. 197 Ruijin Er Road, Shanghai 200025, China. Electronic address: lhm12362@rjh.com.cn.
  • Jiahao Shi
  • Yifan Chen
    Adam Smith Business School, University of Glasgow, Scotland, United Kingdom.
  • Qi Sang
    State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Shanghai Academy of Experimental Medicine, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
  • Ruimin Wang
    State Key Laboratory of Mathematical Engineering and Advanced Computing, Zhengzhou, China.
  • Wanshan Liu
    State Key Laboratory for Oncogenes and Related Genes, School of Biomedical Engineering and Institute of Medical Robotics, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
  • Jiao Wu
    College of Business Administration, Central Michigan University, Mount Pleasant, MI, United States.
  • Yanyan Li
    Department of Center of Integrated Traditional Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Xiaoyu Xu
    Shanghai Advanced Research Institute Chinese Academy of Sciences: Chinese Academy of Sciences Shanghai Advanced Research Institute, Advanced Separation & Conversion on Engineered Nanopore Dynamics Laboratory, CHINA.
  • Chunmeng Ding
    State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Shanghai Academy of Experimental Medicine, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
  • Shouzhi Yang
    State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Shanghai Academy of Experimental Medicine, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
  • Juxiang Zhang
    State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Shanghai Academy of Experimental Medicine, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
  • Renbing Jia
    Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Xianqun Fan
    Department of Ophthalmology, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Kun Qian
    Key Laboratory of Brain Health Intelligent Evaluation and Intervention (Beijing Institute of Technology), Ministry of Education, Beijing, China.
  • Yixiong Zhou
    Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200023, P. R. China.